OBJECTIVES: We aimed to evaluate QoL and Ut in DM2 patients receiving vildagliptin or sulphonylureas (SU) add-on to metformin therapy in a real-world setting. METHODS: In the whole, 229 DM2 patients (mean age – 61.3±9.5 years, 68.1% females) receiving vildagliptin add-on to metformin/GalvusMet (Group 1, n=104) or SU add-on to metformin (Group 2, n=125) were enrolled in the real-world multicenter observational study. Mean disease duration was 5.9±4.1 years, mean HbA1с level – 6.9%±0.8%, late complications were revealed in 27.5% of patients, comorbidities – in 64.6%. All the patients completed SF-36 questionnaire. The Ut scores were calculated for each patient on the basis of SF-6D questionnaire. The SF-6D utility indexes were obtained from SF-36 data. The mean Ut for each treatment group was calculated with adjustment for gender, age, comorbidities, late complications and HbA1с level. Group comparisons were made using General linear models with adjustment for age, comorbidities and late complications. RESULTS:  It was shown that patients in Group 1 had higher QoL by the majority of SF-36 scales: role physical functioning – 74.3 vs 50.3; bodily pain – 82.9 vs 69.1; general health – 56.5 vs 47.7; vitality – 64.4 vs 56.0; social functioning – 83.7 vs 72.5; role emotional functioning – 86.1 vs 58.4 (p<0.05). Integral QoL Index in Group 1 was higher – 0.525 vs 0.351 (p<0.001). The significant difference between Ut values for two groups was revealed: the mean Ut for Group 1 was higher as compared to mean Ut for Group 2 – 0.757 vs 0.701 (p<0.05). CONCLUSIONS: Results of this real-world study demonstrate benefits of treatment with vildagliptin add-on to metformin/GalvusMet in DM2 patients as compared to SU add-on to metformin in terms of better QoL and higher health utility. The data obtained may be used for cost-utility analysis and be further applied for health technology assessment.